Search CTL/CD8+ T-Cell Epitope Database

Found 6 matching records:

Displaying record number 59888

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location	Pol(126-133)
Epitope	`KAIGTVLV`	Epitope Alignment
Epitope Name	KV8
Species (MHC/HLA)	human(B3501, B3508)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
KAIGTVLV had a significantly positive association with HLA B*3501,B*3508; it was recognized by 6/39 B*3501,B*3508-positive subjects and 12/302 B*3501,B*3508-negative subjects.

References

Pereyra2014 Florencia Pereyra, David Heckerman, Jonathan M. Carlson, Carl Kadie, Damien Z. Soghoian, Daniel Karel, Ariel Goldenthal, Oliver B. Davis, Charles E. DeZiel, Tienho Lin, Jian Peng, Alicja Piechocka, Mary Carrington, and Bruce D. Walker. HIV Control Is Mediated in Part by CD8+ T-Cell Targeting of Specific Epitopes. J. Virol., 88(22):12937-12948, Nov 2014. PubMed ID: 25165115. Show all entries for this paper.

Displaying record number 54130

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location
Epitope	`KAIGTVLV`	Epitope Alignment
Species (MHC/HLA)	human(B*57)
Immunogen
Experimental methods
Keywords	optimal epitope

Notes

C. Brander notes that this is an B*57 epitope.

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 59138

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location	Protease
Epitope	`KAIGTVLV`	Epitope Alignment
Epitope Name	KV8
Subtype	B
Species (MHC/HLA)	human(B*57)
Immunogen	HIV-1 infection
Country	Germany
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	elite controllers

Notes

In a follow-up on the anonymous 1999 Berlin patient (not Timothy Brown of 2008), viral replication suppression was seen after 15 years of absence of ART. Half the HIV-specific CTL responses in this patient were restricted by HLA-B*57, with the most immunodominant being against Nef HW9, HTQGYFPDW.
Patient autologous sequence of B*57-restricted Protease KV8, KAIGTVLV, elicited a CTL response of >500 sfu/10<sup>6</sup> PBMC when tested by EliSpot.

References

Jessen2014 Heiko Jessen, Todd M. Allen, and Hendrik Streeck. How a Single Patient Influenced HIV Research — 15-Year Follow-Up. N. Engl. J. Med., 370(7):682-683, 13 Feb 2014. PubMed ID: 24521131. Show all entries for this paper.

Displaying record number 59300

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location	Protease
Epitope	`KAIGTVLV`	Epitope Alignment
Epitope Name	KV8
Species (MHC/HLA)	human(B*57)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	rate of progression

Notes

620 patients in early/acute stages of infection were screened for Elispot responses to optimally defined epitopes to find associations between specific CTL responses and long-term control of HIV-1. Seven epitope-specific responses were associated with delayed initiation of ART, and 12 were associated with a more rapid initiation of therapy. While initial viremia, HLA Class I genotype and viral set points were associated, breadth and magnitude of response did not influence early viral set point. A broader CTL response to Gag, however, associates with slower disease progression.
Initial specificity of CTL response rather than restricting HLA-I molecule contributes to disease control.
The HLA-B*57-restricted epitope KAIGTVLV was associated with accelerated initiation of ART.

References

Streeck2014 Hendrik Streeck, Richard Lu, Noor Beckwith, Mark Milazzo, Michelle Liu, Jean-Pierre Routy, Susan Little, Heiko Jessen, Anthony D. Kelleher, Frederick Hecht, Rafick-Pierre Sekaly, Galit Alter, David Heckerman, Mary Carrington, Eric S. Rosenberg, and Marcus Altfeld. Emergence of Individual HIV-Specific CD8 T Cell Responses during Primary HIV-1 Infection Can Determine Long-Term Disease Outcome. J. Virol., 88(21):12793-12801, Nov 2014. PubMed ID: 25165102. Show all entries for this paper.

Displaying record number 59889

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location	Pol(126-133)
Epitope	`KAIGTVLV`	Epitope Alignment
Epitope Name	KV8
Species (MHC/HLA)	human(B*57)
Immunogen	HIV-1 infection
Experimental methods	CD8 T-cell Elispot - IFNγ, Flow cytometric T-cell cytokine assay
Keywords	rate of progression, optimal epitope

Notes

Correlation between HLA class I and spontaneous control of HIV-1 was significant for 7-8 epitopes when 341 chronic, HIV-infected subjects, divided into controllers and non-controllers, were tested for EliSpot responses to 257 optimally defined epitopes. 21 epitopes were associated with viral progression. Protective epitopes tend to cluster in regions of critical stability for the protein, therefore constraining escape.
KAIGTVLV had a significantly positive association with HLA B*57; it was recognized by 8/99 B*57-positive subjects and 4/203 B*57-negative subjects.

References

Displaying record number 53668

HXB2 Location	Pol(126-133) Protease(70-77) DNA(2460..2483)	Pol Epitope Map
Author Location	Protease
Epitope	`KAIGTVLV`	Epitope Alignment
Epitope Name	KV8
Subtype	B, C
Species (MHC/HLA)	human(B57, B58, B63)
Immunogen	HIV-1 infection
Patient MHC/HLA	A23, A30, B42, B57, Cw17
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	HLA cross-presentation, optimal epitope

Notes

HLA-B63-positive subjects were shown to be able to generate CTL responses early in acute HIV infection and to control HIV replication in the absence of antiretroviral treatment. Since HLA-B63 shares the epitope binding motif of HLA-B57 and -B58, it was shown that HLA-B63-positive individuals mounted CTL responses to previously identified B57-restricted epitopes, as well as novel, B63-restricted epitopes. Moreover, these novel B63-restricted epitopes can also be presented by HLA-B57 and -B58.
HLA-B63/57/58 epitope containing the B58 supertype binding motif. Significantly more often recognized by B63-positive subjects than by negative subjects. Optimal epitope was defined in a person who was B57+.

References

Frahm2005a Nicole Frahm, Sharon Adams, Photini Kiepiela, Caitlyn H. Linde, Hannah S. Hewitt, Mathias Lichterfeld, Kaori Sango, Nancy V. Brown, Eunice Pae, Alysse G. Wurcel, Marcus Altfeld, Margaret E. Feeney, Todd M. Allen, Timothy Roach, M. Anne St. John, Eric S. Daar, Eric Rosenberg, Bette Korber, Francesco Marincola, Bruce D. Walker, Philip J. R. Goulder, and Christian Brander. HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. J. Virol., 79(16):10218-10225, Aug 2005. PubMed ID: 16051815. Show all entries for this paper.